Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLSD Clearside Biomedical	$0.39 -2.2%	$0.59	$0.29 ▼ $1.65	$31.03M	2.08	585,287 shs	193,928 shs
DYAI Dyadic International	$0.93 +2.9%	$0.95	$0.71 ▼ $2.20	$32.74M	0.89	143,479 shs	186,440 shs
ITRM Iterum Therapeutics	$0.72 +5.7%	$0.87	$0.66 ▼ $3.02	$30.51M	2.85	1.08 million shs	492,607 shs
TSBX Turnstone Biologics	$0.36	$0.36	$0.29 ▼ $2.42	$8.22M	1.36	142,319 shs	N/A

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLSD Clearside Biomedical	-2.20%	-5.15%	-13.14%	-50.44%	-61.72%
DYAI Dyadic International	+2.91%	+14.94%	-16.13%	-10.05%	-37.52%
ITRM Iterum Therapeutics	+5.66%	-4.96%	-7.44%	-26.33%	-35.54%
TSBX Turnstone Biologics	0.00%	0.00%	+0.71%	+9.84%	-51.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLSD Clearside Biomedical	2.6647 of 5 stars	4.1	3.0	3.5	0.0	0.0
DYAI Dyadic International	3.4252 of 5 stars	3.5	5.0	2.7	3.3	0.0
ITRM Iterum Therapeutics	2.1659 of 5 stars	3.5	3.0	1.9	1.7	0.0
TSBX Turnstone Biologics	3.088 of 5 stars	2.8	5.0	0.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLSD Clearside Biomedical	2.17	Hold	$4.20	986.39% Upside
DYAI Dyadic International	3.00	Buy	$6.00	544.47% Upside
ITRM Iterum Therapeutics	3.00	Buy	$9.00	1,146.54% Upside
TSBX Turnstone Biologics	1.50	Reduce	$0.45	26.76% Upside

Current Analyst Ratings Breakdown

Latest TSBX, ITRM, CLSD, and DYAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
7/18/2025	CLSD Clearside Biomedical	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/18/2025	CLSD Clearside Biomedical	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$2.00
7/17/2025	CLSD Clearside Biomedical	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold	$3.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLSD Clearside Biomedical	$1.66M	18.28	N/A	N/A	($0.62) per share	-0.62
DYAI Dyadic International	$3.49M	9.65	N/A	N/A	($0.01) per share	-93.10
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	($0.09) per share	N/A
TSBX Turnstone Biologics	$19.31M	0.43	N/A	N/A	$0.64 per share	0.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLSD Clearside Biomedical	-$34.35M	-$0.37	N/A	N/A	N/A	-665.19%	N/A	-124.15%	11/11/2025 (Estimated)
DYAI Dyadic International	-$5.81M	-$0.19	N/A	N/A	N/A	-134.84%	-355.39%	-60.66%	11/11/2025 (Estimated)
ITRM Iterum Therapeutics	-$24.77M	-$0.85	N/A	∞	N/A	N/A	N/A	-65.01%	11/13/2025 (Estimated)
TSBX Turnstone Biologics	-$70.84M	-$2.05	N/A	N/A	N/A	N/A	-171.86%	-128.13%	N/A

Latest TSBX, ITRM, CLSD, and DYAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	DYAI Dyadic International	-$0.06	-$0.06	N/A	-$0.06	$0.60 million	$0.97 million
8/8/2025	Q2 2025	CLSD Clearside Biomedical	-$0.12	-$0.06	+$0.06	-$0.06	$0.50 million	$0.49 million
8/8/2025	Q2 2025	TSBX Turnstone Biologics	-$0.16	-$0.24	-$0.08	-$0.24	N/A	N/A
8/5/2025	Q2 2025	ITRM Iterum Therapeutics	-$0.13	-$0.16	-$0.03	-$0.16	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	N/A
TSBX Turnstone Biologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLSD Clearside Biomedical	N/A	3.87	3.87
DYAI Dyadic International	5.40	2.02	2.02
ITRM Iterum Therapeutics	N/A	2.69	2.52
TSBX Turnstone Biologics	N/A	3.33	3.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLSD Clearside Biomedical	18.75%
DYAI Dyadic International	27.95%
ITRM Iterum Therapeutics	9.21%
TSBX Turnstone Biologics	52.51%

Insider Ownership

Company	Insider Ownership
CLSD Clearside Biomedical	6.70%
DYAI Dyadic International	29.50%
ITRM Iterum Therapeutics	2.40%
TSBX Turnstone Biologics	32.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLSD Clearside Biomedical	30	78.51 million	73.25 million	Optionable
DYAI Dyadic International	7	36.19 million	25.51 million	Optionable
ITRM Iterum Therapeutics	10	44.66 million	43.59 million	Not Optionable
TSBX Turnstone Biologics	82	23.14 million	15.71 million	Not Optionable

TSBX, ITRM, CLSD, and DYAI Headlines

Recent News About These Companies

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Turnstone Biologics Corp. (NASDAQ: TSBX)

June 30, 2025 | globenewswire.com

Turnstone Biologics Corp. Enters Merger Agreement with XOMA

June 27, 2025 | tipranks.com

XOMA stock rises after acquisition of Turnstone Biologics

June 27, 2025 | au.investing.com

Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps

June 27, 2025 | msn.com

TSBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Turnstone Biologics Corp. Is Fair to Shareholders

June 27, 2025 | businesswire.com

Turnstone Biologics Corp. (TSBX) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent ...

May 8, 2025 | gurufocus.com

Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights

May 8, 2025 | globenewswire.com

Turnstone Biologics reports Q4 EPS (56c) vs (73c) last year

March 31, 2025 | markets.businessinsider.com

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

March 28, 2025 | investing.com

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

March 28, 2025 | globenewswire.com

Turnstone Biologics stock plunges to 52-week low of $0.4

February 11, 2025 | msn.com

Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?

February 7, 2025 | zacks.com

Turnstone Biologics to explore strategic alternatives

February 6, 2025 | thepharmaletter.comT

Turnstone ends last remaining clinical program due to costs, plots more layoffs

February 5, 2025 | fiercebiotech.comF

Turnstone Biologics halts TIDAL-01 development, seeks alternatives

February 5, 2025 | msn.com

Turnstone Biologics downgraded to Neutral from Overweight at Piper Sandler

February 5, 2025 | markets.businessinsider.com

Turnstone Biologics Corp (TSBX) Stock: A Deeper Look at Its True Potential

February 5, 2025 | bovnews.comB

Turnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives Review

February 4, 2025 | quiverquant.comQ

Turnstone Biologics Announces Plans to Explore Strategic Alternatives

February 4, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSBX, ITRM, CLSD, and DYAI Company Descriptions

Clearside Biomedical NASDAQ:CLSD

$0.39 -0.01 (-2.20%)

Closing price 08/27/2025 04:00 PM Eastern

Extended Trading

$0.40 +0.01 (+2.17%)

As of 08/27/2025 06:50 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Dyadic International NASDAQ:DYAI

$0.93 +0.03 (+2.91%)

Closing price 08/27/2025 04:00 PM Eastern

Extended Trading

$0.93 0.00 (0.00%)

As of 08/27/2025 05:36 PM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Iterum Therapeutics NASDAQ:ITRM

$0.72 +0.04 (+5.66%)

Closing price 08/27/2025 04:00 PM Eastern

Extended Trading

$0.73 +0.01 (+0.97%)

As of 08/27/2025 07:50 PM Eastern

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Turnstone Biologics NASDAQ:TSBX

$0.36 0.00 (0.00%)

As of 08/11/2025

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time